Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial

Fabrice André, Ruth O'Regan, Mustafa Ozguroglu, Masakazu Toi, Binghe Xu, Guy Jerusalem, Norikazu Masuda, Sharon Wilks, Francis Arena, Claudine Isaacs, Yoon Sim Yap, Zsuzsanna Papai, Istvan Lang, Anne Armstrong, Guillermo Lerzo, Michelle White, Kunwei Shen, Jennifer Litton, David Chen, Yufen ZhangShyanne Ali, Tetiana Taran, Luca Gianni

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): A randomised, double-blind, placebo-controlled phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences